Dr. Daniel Morganstern, a renowned breast cancer subspecialist, will join the outstanding oncology team at Starling Physicians in June. He previously practiced at the Dana-Farber Cancer Institute. (contributed photo)
ROCKY HILL, CT - As a recognized leader in cancer care across Connecticut, Starling Physicians is pioneering a new era of personalized medicine. Starting in June, Dr. Daniel Morganstern will join the team as a breast cancer subspecialist as they further their understanding of the molecular heterogeneity of breast cancer and other cancers. Within breast cancer there is an emerging consensus that there are many clinically meaningful subtypes, each unique and requiring a customized treatment plan.
Dr. Morganstern comes from the Dana-Farber Cancer Institute where he spent the last 14 years as a leading expert in the field of breast cancer, cancer genetics, and cancer prevention. During this time, he also served as the Clinical Lead for the Women’s Cancer Program inpatient service at Brigham and Women’s Hospital, and co-founded the Breast Cancer Prevention Center at Dana-Farber. He played an active role in clinical trials at Dana-Farber and is interested in strengthening current clinical trial opportunities in the Greater Hartford area. He will see patients in Wethersfield and Bloomfield.
“While I have enjoyed involvement at a larger tertiary academic institution, I believe that Starling’s somewhat smaller scale provides an opportunity to enhance the patient experience,” shares Dr. Morganstern. “Starling’s personalized approach to patient care that is based on collaboration resonates with me. I am excited to work with the oncology team, outstanding physicians across multiple specialties, and community-based infusion nurses to deliver the best care possible to our patients.”
Dr. Morganstern will partner with Starling’s strong team of hematologists and oncologists which includes 15 physicians and midlevels and a team of over 100 employees that treat patients in seven central Connecticut offices. Starling offers three state-of-the-art infusion centers in Wethersfield, Enfield, and New Britain, and has 46 infusion chairs.
“We are thrilled to have someone of Dr. Morganstern’s stature join our practice,” said Dr. Jarrod Post, CEO of Starling Physicians. “He is at the forefront of research in this field and we will benefit from his insights. He also shares our philosophy that healthcare is relationship driven, with the patient/provider relationship at the core of everything we do.”
Dr. Morganstern further explains, “I believe in meeting patients where they are in terms of their knowledge, lifestyle, and psychological state. I work with each patient as an individual and place a strong emphasis on education and empowering women so they can make informed decisions. Now, more than ever, there are many expanded treatment options and I help women make the choice that is right for their needs.”
The oncology team will welcome another talented new physician, Dr. Lawrence Giove, in August. He joins Starling from training at Northwell Health (formerly North Shore-LIJ) in New York and will provide oncology care to patients in New Britain, Enfield, and Wethersfield.
“Starling’s main goal is to continue providing comprehensive, cutting edge cancer care while staying ahead of the curve,” said Dr. Todd Alekshun, a hematologist/oncologist at Starling. “We are growing, and offer complete care for adult cancers and blood-related disorders.”
Starling Physicians was formed by the unification of Grove Hill Medical Centers and Connecticut Multispecialty Group. The practice is owned and led by physicians with a deep commitment to providing the highest quality care, while building enduring relationships with their patients. More than 250 physicians and other medical practitioners provide primary and specialty care across 25 specialties in 30 locations across Connecticut. For more information, visitwww.starlingphysicians.com